With improved longevity, cystic fibrosis (CF)-related diabetes (CFRD) has emerged as the most common nonpulmonary complication of CF. Patients with CFRD are frequently admitted to the hospital with infections and deterioration of pulmonary function, during which time glycemic control might have an impact on pulmonary function, recovery from infection, and survival.
Methods and Results:
In an attempt to share our insight into inpatient management of CFRD, this article summarizes the experience of our inpatient glucose management team with hospital management of 121 adult CFRD patients who were hospitalized on 410 occasions at the University of Colorado Hospital between January 2009 and September 2011. This is a retrospective chart review descriptive study of inpatient management of CFRD in our center. Our cohort includes CFRD patients treated with basal and mealtime insulin through multiple daily injections or continuous subcutaneous insulin infusion (CSII), as well as patients receiving steroids or enteral nutrition, which adds complexity to the management of CFRD during hospitalization.
Conclusions:
Multiple hospitalizations and intensive inpatient management of CF are integral elements of treatment. Inpatient therapy for CFRD requires a customized approach that is uniquely different from that of type 1 or type 2 diabetes. Our experience highlights clinical circumstances such as irregular food intake, high dose steroid therapy, and supplemental tube feeding. For many patients, it is possible to continue CSII therapy during hospitalization through a combination of mutual trust between the patient and hospital staff and oversight provided by the glucose management team.
Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med. 1993; 329 (18): 1308–13.
2.
WelshMJTsuiLCBoatTFBeaudetAL.Cystic fibrosis. In: ScriverCRBeaudetALSlyWSValleD, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th edition. Texas: McGraw-Hill; 1995. p. 3799–876.
3.
MoranABeckerDCasellaSJGottliebPAKirkmanMSMarshallBCSlovisB; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes. Diabetes Care. 2010; 33 (12): 2677–83.
NoronhaRMCalliariLEDamacenoNMuramatuLHMonteO.Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD). Arq Bras Endocrinol Metabol. 2011; 55 (8): 613–21.
6.
MoranADunitzJNathanBSaeedAHolmeBThomasW.Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32 (9): 1626–31. Epub 2009 Jun 19.
LippeBMSperlingMADooleyRR.Pancreatic alpha and beta cell functions in cystic fibrosis. J Pediatr. 1977; 90 (5): 751–5.
10.
MoranADiemPKleinDJLevittMDRobertsonRP.Pancreatic endocrine function in cystic fibrosis. J Pediatr. 1991; 118 (5): 715–23.
11.
ArrigoTCucinottaDNibaliS ContiDi CesareEDi BenedettoAMagazzùGDe LucaF.Longitudinal evaluation of glucose tolerance and insulin secretion in non-diabetic children and adolescents with cystic fibrosis: results of a two-year follow-up. Acta Paediatr. 1993; 82 (3): 249–53.
12.
LombardoFDe LucaFRosanoMSferlazzasCLucantoCArrigoTMessinaMFCrisafulliGWasniewskaMValenziseMCucinottaD.Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol. 2003; 149 (1): 53–9.
13.
BismuthELabordeKTaupinPVelhoGRibaultVJennaneFGrassetESermetIde BlicJLenoirGRobertJJ.Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008; 152 (4): 540–5, 545.e1. Epub 2007 Nov 26.
14.
HardinDSLeBlancALukenboughSSeilheimerDK.Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr. 1997; 130 (6): 948–56.
15.
HardinDSLeblancAMarshallGSeilheimerDK.Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001; 281 (5): E1022–8.
16.
NathanBMoranA.Treatment recommendations for cystic fibrosis-related diabetes: too little, too late?Thorax. 2011; 66 (7): 555–6. Epub 2011 May 4.
17.
MoranABrunzellCCohenRCKatzMMarshallBCOnadyGRobinsonKASabadosaKAStecenkoASlovisB; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33 (12): 2697–708.
18.
O'RiordanSMRobinsonPDDonaghueKCMoranA; ISPAD Clinical Practice Consensus. Management of cystic fibrosis-related diabetes. Pediatr Diabetes. 2008; 9 (4 Pt 1): 338–44.
MillaCEWarwickWJMoranA.Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000; 162 (3 Pt 1): 891–5.
21.
NtimbaneTKrishnamoorthyPHuotCLegaultLJacobSVBrunetSLevyEGuéraudFLandsLCComteB.Oxidative stress and cystic fibrosis-related diabetes: a pilot study in children. J Cyst Fibros. 2008; 7 (5): 373–84. Epub 2008 Apr 16.
22.
MillaCEBillingsJMoranA.Diabetes is associated with dramatically decreased survival in female but not in male subjects with cystic fibrosis. Diabetes Care. 2005; 28 (9): 2141–4.
23.
KochCRainisioMMadessaniUHarmsHKHodsonMEMastellaGMcKenzieSGNavarroJStrandvikB; Investigators of the European Epidemiology Registry of Cystic Fibrosis. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiology Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001; 32 (5): 343–50.
24.
AdlerAIShineBHaworthCLeelarathnaLBiltonD.Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care. 2011; 34 (7): 1577–8. Epub 2011 May 18.
25.
ChamnanPShineBSHaworthCSBiltonDAdlerAI.Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010; 33 (2): 311–6. Epub 2009 Nov 16.
26.
Van den BergJMKouwenbergJMHeijermanHG.Demographics of glucose metabolism in cystic fibrosis. J Cystic Fibrosis. 2009; 8 (4): 276–9. Epub 2009 May 24.
27.
SeggelkeSAGibbsJDrazninB.Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011; 6 (3): 175–6. doi: 10.1002/jhm.874.
28.
RafiMChapmanKStewartCKellyEHannaAWilsonDCTullisEPencharzPB.Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr. 2005; 81 (2): 421–6.
29.
RamseyBWFarrellPMPencharzP.Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. Am J Clin Nutr. 1992; 55 (1): 108–16.
30.
HsiaESeggelkeSAGibbsJRasouliNDrazninB.Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract. 2011; 26 (6): 714–7.
31.
BevierWCZisserHCJovanovicLFinanDAPalermCCSeborgDEDoyleFJ3rd. Use of continuous glucose monitoring to estimate insulin requirement in patients with type 1 diabetes mellitus during a short course of prednisone. J Diabetes Sci Technol. 2008; 2 (4): 578–83.
32.
RolonMABenaliKMunckANavarroJClementATubiana-RufiNCzernichowPPolakM.Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001; 90 (8): 860–7.
33.
BrennanALGyiKMWoodDMJohnsonJHollimanRAinesDLPhillipsBJGeddesDMHodsonMEBakerEH.Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. 2007; 6 (2): 101–9. Epub 2006 Jul 17.
MoranAHardinDRodmanDAllenHFBeallRJBorowitzDBrunzellCCampbellPW3rdChesrownSEDuchowCFinkRJFitzsimmonsSCHamiltonNHirschIHowenstineMSKleinDJMadhunZPencharzPBQuittnerALRobbinsMKShindlerTSchisselKSchwarzenbergSJStallingsVAZipfWBTullisDE.Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diab Res Clin Pract. 1999; 45 (1): 61–73.
